STCube

STCube EBITDA per Share

The EBITDA per Share of STCube (052020.KQ) as of Oct 24, 2026 is -345.52 KRW. In the previous year, EBITDA per Share was -316.57 KRW — a change of 9.15% (lower).

EBITDA per Share

-345.52KRW

YoY

9.15%

Last updated:

EBITDA per Share of STCube is 2025 -345.52 KRW. EBITDA per Share of STCube was 2024 -316.57 KRW. It decreases by 9.15% lower compared to the previous year.

The STCube EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-354.29 KRW
Jan 1, 2019
-305.54 KRW
Jan 1, 2020
-334.06 KRW
Jan 1, 2021
-509.12 KRW
Jan 1, 2022
-397.37 KRW
Jan 1, 2023
-543.45 KRW
Jan 1, 2024
-316.57 KRW
Jan 1, 2025
-345.52 KRW
The STCube EBITDA per Share history
YEAREBITDA per ShareYoY
-345.52KRW+9.15%
-316.57KRW-41.75%
-543.45KRW+36.76%
-397.37KRW-21.95%
-509.12KRW+52.40%
-334.06KRW+9.34%
-305.54KRW-13.76%
-354.29KRW-22.57%
-457.58KRW+518.35%
-74.00KRW-86.05%
-530.36KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

EBITDA per Share of STCube is -345.52 KRW in 2025.

EBITDA per Share of STCube changed from -316.57 KRW to -345.52 KRW, representing a 9.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share STCube since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — STCube

All Key Metrics — STCube